UnitedHealthcare Coverage Policy Undercutting Neulasta Biosimilars Draws Concerns

 
• By Cathy Kelly

US insurer’s commercial plans will favor the originator drug over biosimilars in return for a price concession from Amgen, while UnitedHealthcare’s Medicare Advantage plans will prefer biosimilars in several categories.

House of mirrors
What does UnitedHealthcare's decision on Neulasta and its biosimilars reflect? That depends on where you stand.

More from Market Access

More from Pink Sheet